IL235927A - Composition comprising a vascular disrupting agent and an agent which targets hypoxia for cancer treatment - Google Patents
Composition comprising a vascular disrupting agent and an agent which targets hypoxia for cancer treatmentInfo
- Publication number
- IL235927A IL235927A IL235927A IL23592714A IL235927A IL 235927 A IL235927 A IL 235927A IL 235927 A IL235927 A IL 235927A IL 23592714 A IL23592714 A IL 23592714A IL 235927 A IL235927 A IL 235927A
- Authority
- IL
- Israel
- Prior art keywords
- agent
- composition
- cancer treatment
- vascular disrupting
- targets hypoxia
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2012902291A AU2012902291A0 (en) | 2012-06-01 | Combination Therapy | |
| PCT/AU2013/000581 WO2013177633A1 (en) | 2012-06-01 | 2013-06-03 | Combination therapy involving a vascular disrupting agent and an agent which targets hypoxia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL235927A0 IL235927A0 (en) | 2015-01-29 |
| IL235927A true IL235927A (en) | 2017-11-30 |
Family
ID=49672192
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL235927A IL235927A (en) | 2012-06-01 | 2014-11-26 | Composition comprising a vascular disrupting agent and an agent which targets hypoxia for cancer treatment |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20150133401A1 (en) |
| EP (1) | EP2854796B1 (en) |
| JP (1) | JP6005855B2 (en) |
| CN (1) | CN104703595B (en) |
| AU (2) | AU2013204313C1 (en) |
| CA (1) | CA2874778A1 (en) |
| HK (1) | HK1207286A1 (en) |
| IL (1) | IL235927A (en) |
| NZ (1) | NZ630465A (en) |
| WO (1) | WO2013177633A1 (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10137105B2 (en) | 2015-03-05 | 2018-11-27 | Bionomics Limited | Combination treatment protocol |
| RU2736045C2 (en) | 2015-03-06 | 2020-11-11 | Бейондспринг Фармасьютикалс, Инк. | Method of treating cancer associated with a ras mutation |
| BR112017018964A2 (en) * | 2015-03-06 | 2018-05-22 | Beyondspring Pharmaceuticals Inc | use of plinabulin and methods to treat brain tumor |
| WO2017011399A1 (en) | 2015-07-13 | 2017-01-19 | Beyondspring Pharmaceuticals, Inc | Plinabulin compositions |
| AU2017217426B2 (en) | 2016-02-08 | 2022-12-01 | Beyondspring Pharmaceuticals, Inc. | Compositions containing tucaresol or its analogs |
| BR112018074990A2 (en) | 2016-06-06 | 2019-03-12 | Beyondspring Pharmaceuticals, Inc. | composition, uses and method for reducing neutropenia |
| CN110431135A (en) | 2017-01-06 | 2019-11-08 | 大连万春布林医药有限公司 | Tubulin binding compound and its therapeutical uses |
| US11400086B2 (en) | 2017-02-01 | 2022-08-02 | Beyondspring Pharmaceuticals, Inc. | Method of reducing chemotherapy-induced neutropenia |
| EP3743074A4 (en) | 2018-01-24 | 2021-12-15 | Beyondspring Pharmaceuticals Inc. | Composition and method for reducing thrombocytopenia via the administration of plinabulin |
| CN110680824A (en) * | 2018-07-05 | 2020-01-14 | 深圳艾欣达伟医药科技有限公司 | Anticancer medical application of Evoxamine |
| CN109675039A (en) * | 2018-12-21 | 2019-04-26 | 中国科学院长春应用化学研究所 | Pharmaceutical composition, anti-tumor drug and application |
| CN112755188B (en) * | 2019-11-01 | 2022-03-08 | 中国科学院微生物研究所 | Application of SHMT2 inhibitor in preparation of medicines for inhibiting growth and metastasis of bladder cancer cells |
| WO2023025291A1 (en) | 2021-08-27 | 2023-03-02 | 深圳艾欣达伟医药科技有限公司 | Lyophilized formulation solution and lyophilized formulation, and method and use thereof |
| WO2023025312A1 (en) | 2021-08-27 | 2023-03-02 | 深圳艾欣达伟医药科技有限公司 | Parp inhibitor-resistant patient treated with th-302 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5340062A (en) | 1992-08-13 | 1994-08-23 | Harmon Industries, Inc. | Train control system integrating dynamic and fixed data |
| US5886025A (en) | 1997-03-06 | 1999-03-23 | Baylor University | Anti-mitotic agents which inhibit tubulin polymerization |
| US6162930A (en) | 1998-03-06 | 2000-12-19 | Baylor University | Anti-mitotic agents which inhibit tubulin polymerization |
| US6849656B1 (en) | 1999-09-17 | 2005-02-01 | Baylor University | Indole-containing and combretastatin-related anti-mitotic and anti-tubulin polymerization agents |
| AUPR283801A0 (en) | 2001-02-01 | 2001-03-01 | Australian National University, The | Chemical compounds and methods |
| US7071190B2 (en) | 2002-02-15 | 2006-07-04 | Rigel Pharmaceuticals, Inc. | Inhibitors to tubulin polymerization |
| US7456214B2 (en) | 2004-05-03 | 2008-11-25 | Baylor University | Chromene-containing compounds with anti-tubulin and vascular targeting activity |
| CA2597447C (en) | 2005-02-14 | 2014-03-25 | Bionomics Limited | Novel tubulin polymerisation inhibitors |
| JP5354775B2 (en) | 2005-06-14 | 2013-11-27 | ベイラー ユニバーシティ | Combretastatin analogs with tubulin binding activity |
| ES2386299T3 (en) * | 2006-02-03 | 2012-08-16 | Bionomics Limited | Benzofurans, benzothiophenes, benzoselenophenes and substituted indoles and their use as inhibitors of tubulin polymerization |
| AU2007332143B2 (en) | 2006-12-11 | 2012-11-08 | Bionomics Limited | Chemical compounds and processes |
| CN102026634B (en) * | 2008-04-10 | 2014-01-22 | 弗吉尼亚州立邦联大学 | Induction of tumor hypoxia for cancer therapy |
| WO2011063469A1 (en) * | 2009-11-27 | 2011-06-03 | Bionomics Limited | Tubulin biomarker assay |
| US20110130367A1 (en) * | 2009-11-27 | 2011-06-02 | Bionomics Limited | Combination Therapy for Treating Proliferative Diseases |
| CA2686587C (en) * | 2009-11-27 | 2018-01-16 | Bionomics Limited | Combination therapy for treating proliferative diseases |
| ES2649340T3 (en) * | 2010-07-12 | 2018-01-11 | Threshold Pharmaceuticals, Inc. | Administration of hypoxia activated drugs and antiangiogenic agents for cancer treatment |
-
2013
- 2013-04-12 AU AU2013204313A patent/AU2013204313C1/en not_active Ceased
- 2013-06-03 CA CA2874778A patent/CA2874778A1/en not_active Abandoned
- 2013-06-03 US US14/404,782 patent/US20150133401A1/en not_active Abandoned
- 2013-06-03 CN CN201380035499.3A patent/CN104703595B/en not_active Expired - Fee Related
- 2013-06-03 WO PCT/AU2013/000581 patent/WO2013177633A1/en active Application Filing
- 2013-06-03 NZ NZ630465A patent/NZ630465A/en not_active IP Right Cessation
- 2013-06-03 JP JP2015514291A patent/JP6005855B2/en not_active Expired - Fee Related
- 2013-06-03 EP EP13797528.0A patent/EP2854796B1/en not_active Not-in-force
- 2013-06-03 AU AU2013270425A patent/AU2013270425A1/en not_active Abandoned
-
2014
- 2014-11-26 IL IL235927A patent/IL235927A/en active IP Right Grant
-
2015
- 2015-08-14 HK HK15107846.4A patent/HK1207286A1/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP2854796A4 (en) | 2015-10-14 |
| CN104703595B (en) | 2017-07-28 |
| AU2013204313C1 (en) | 2016-04-07 |
| NZ630465A (en) | 2015-09-25 |
| AU2013204313A1 (en) | 2013-12-19 |
| JP6005855B2 (en) | 2016-10-12 |
| AU2013270425A1 (en) | 2014-12-18 |
| EP2854796A1 (en) | 2015-04-08 |
| CA2874778A1 (en) | 2013-12-05 |
| AU2013204313B2 (en) | 2015-09-03 |
| HK1207286A1 (en) | 2016-01-29 |
| JP2015518008A (en) | 2015-06-25 |
| WO2013177633A1 (en) | 2013-12-05 |
| IL235927A0 (en) | 2015-01-29 |
| EP2854796B1 (en) | 2018-11-14 |
| CN104703595A (en) | 2015-06-10 |
| US20150133401A1 (en) | 2015-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL235927A (en) | Composition comprising a vascular disrupting agent and an agent which targets hypoxia for cancer treatment | |
| PT2740793T (en) | Drug composition for cancer treatment and/or prevention | |
| EP2818483A4 (en) | Medicinal composition for treating and/or preventing cancer | |
| HK1209798A1 (en) | Compositions and methods for treating cancer | |
| IL234989B (en) | Compounds and compositions thereof for treating cancer | |
| EP2740795A4 (en) | Cancer treatment and/or prevention drug composition | |
| EP2740798A4 (en) | Cancer treatment and/or prevention drug composition | |
| EP2836482A4 (en) | Compositions and methods for treating cancer | |
| EP2890720A4 (en) | Compositions and methods for treating cancer | |
| HUE044611T2 (en) | Pharmaceutical composition for treatment of cancer | |
| HUE045461T2 (en) | Pharmaceutical composition for treatment of cancer | |
| EP2818481A4 (en) | Pharmaceutical composition for treatment and/or prevention of cancer | |
| EP2825239A4 (en) | Catheter having antimicrobial coating | |
| EP2709614A4 (en) | Pharmaceutical compositions and methods for treating cancer | |
| HK1216854A1 (en) | Compositions and methods for treating cancer | |
| EP2823825A4 (en) | Pharmaceutical composition for treating cancer | |
| EP2886122A4 (en) | Agent for treating cancer | |
| SG11201400976WA (en) | Methods and pharmaceutical compositions for treating cancer | |
| SG11201509433RA (en) | Composition comprising a complex of (+)-catechin and amino acid for the treatment and prevention of cancer | |
| HK1207561A1 (en) | Compositions and methods for treating hepatocellular cancer | |
| PL2663318T3 (en) | Pharmaceutical composition for treating cancer | |
| EP2902027A4 (en) | Drug composition for treating tumors and application thereof | |
| EP2841102A4 (en) | Methods and compositions for treating cancer | |
| EP2822593A4 (en) | Compositions and methods for treating cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed |